<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e>, also known as the <z:e sem="disease" ids="C1262289" disease_type="Disease or Syndrome" abbrv="">dysmetabolic syndrome</z:e>, syndrome X or the <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> syndrome, refers to the clustering of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> risk factors that are present in many individuals who are at increased risk for both cardiovascular events and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">Prediabetic</z:e> subjects typically exhibit an atherogenic pattern of cardiovascular risks that is associated with <z:e sem="disease" ids="C0020459" disease_type="Disease or Syndrome" abbrv="">hyperinsulinaemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Thus, identification of components of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> is important if patients are to be treated early enough to prevent cardiovascular events and other complications related to <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Therapies targeted to specific components of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> such as improving glycaemic control, managing <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> and reducing the prothrombotic state should help to minimize cardiovascular risk, particularly if initiated early </plain></SENT>
<SENT sid="4" pm="."><plain>Traditional pharmacologic agents used to manage the individual components of the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> do not typically impact the other components </plain></SENT>
<SENT sid="5" pm="."><plain>The <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi>, a new class of agents that improve <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, have the ability, in addition to their <z:chebi fb="105" ids="17234">glucose</z:chebi>-lowering effects, to exert several powerful anti-atherogenic properties, including anti-inflammatory effects in the vascular endothelium, redistribution of visceral fat and reduction of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, <z:e sem="disease" ids="C0020459" disease_type="Disease or Syndrome" abbrv="">hyperinsulinaemia</z:e> and hyperproinsulinaemia </plain></SENT>
<SENT sid="6" pm="."><plain>This makes the <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> ideal candidates for the early treatment of many components associated with the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
</text></document>